Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 8Leukemia, Myeloid, Acute 8Multiple Myeloma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Hematologic Neoplasms 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hodgkin Disease 5Waldenstrom Macroglobulinemia 4Myeloproliferative Disorders 4Lymphoma, Non-Hodgkin 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Myelomonocytic, Chronic 2Graft vs Host Disease 2Burkitt Lymphoma 2Bronchiolitis Obliterans Syndrome 2Anemia, Aplastic 2Urologic Neoplasms 1Thyroid Neoplasms 1Thrombocythemia, Essential 1Soft Tissue Neoplasms 1Sezary Syndrome 1

Interventions

Cyclophosphamide 23fludarabine 14Rituximab 14Specimen Handling 8Magnetic Resonance Spectroscopy 7Doxorubicin 7pirtobrutinib 6Vincristine 6Prednisone 6zanubrutinib 4polatuzumab vedotin 4obinutuzumab 4Nivolumab 4Etoposide 4Dexamethasone 4Biopsy 4tazemetostat 3tafasitamab 3pembrolizumab 3ibrutinib 3glofitamab 3fludarabine phosphate 3acalabrutinib 3Immunotherapy, Adoptive 3Bendamustine Hydrochloride 3venetoclax 2pomalidomide 2etoposide phosphate 2cemiplimab 2Prednisolone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Sirolimus × 90 days × Clear all
NCT06528301 2026-05-28

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Umoja Biopharma

Phase 1 Recruiting
106 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡